Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia

References

• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
   PubMed Web of Science ®Google Scholar
• Chatzikonstantinou T, Kapetanakis A, Scarfò L, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study. Leukemia. 2021;35(12):3444–3454.
   PubMedGoogle Scholar
• Arruga F, Gyau BB, Iannello A, et al. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020;21(5):1825.
   PubMed Web of Science ®Google Scholar
• Chumsri S, Advani PP, Pai TS, et al. Humoral responses after SARS-CoV-2 mRNA vaccination and breakthrough infection in cancer patients. Mayo Clin Proceedings Innov Qual Outcomes. 2022;6(2):120–125.
   PubMedGoogle Scholar
• Herishanu Y, Rahav G, Levi S, Israeli CLL Study Group, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139(5):678–685.
   PubMed Web of Science ®Google Scholar
• Parry H, Bruton R, Roberts T, et al. COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell. 2022;40(6):584–586.
   PubMedGoogle Scholar
• Mellinghoff SC, Robrecht S, Mayer L, et al. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia. 2022;36(2):562–565.
   PubMedGoogle Scholar
• Ryan JE, Ovsyannikova IG, Poland GA. Detection of measles virus-specific interferon-gamma-secreting T-cells by ELISPOT. Methods Mol Biol. 2005;302:207–218.
   PubMedGoogle Scholar
• Umlauf BJ, Pinsky NA, Ovsyannikova IG, et al. Detection of vaccinia virus-specific IFNγ and IL-10 secretion from human PBMCs and CD8+ T cells by ELISPOT. Methods Mol Biol. 2012;792:199–218.
   PubMedGoogle Scholar
• Crooke SN, Ovsyannikova IG, Kennedy RB, et al. Identification of naturally processed zika virus peptides by mass spectrometry and validation of memory T cell recall responses in zika convalescent subjects. PLOS One. 2021;16(6):e0252198.
   PubMedGoogle Scholar
• Quach HQ, Ovsyannikova IG, Poland GA, et al. Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine. Sci Rep. 2022;12(1):15401.
   PubMedGoogle Scholar
• Terpos E, Fotiou D, Karalis V, et al. SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies. Am J Hematol. 2022 Oct;97(10):1300–1308.
   Google Scholar
• Chang A, Akhtar A, Linderman SL, et al. Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 2022;40(26):3020–3031.
   PubMedGoogle Scholar
• Edara V-V, Manning KE, Ellis M, et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Reports Med. 2022;3(2):100529.
   PubMedGoogle Scholar
• Muik A, Lui BG, Wallisch A-K, et al. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022;375(6581):678–680.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet. 2022 Mar 5;399(10328):905–907.
   Google Scholar
• Qu P, Faraone JN, Evans JP, et al. Durability of booster mRNA vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(14):1329–1331.
   PubMedGoogle Scholar
• Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022;14(637).
   PubMedGoogle Scholar
• Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection. JAMA Netw Open. 2022;5(9):e2231778.
   PubMedGoogle Scholar
• Re D, Seitz-Polski B, Brglez V, et al. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat Commun. 2022;13(1):864.
   PubMed Web of Science ®Google Scholar
• Vogel E, Kocher K, Priller A, et al. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. EBioMedicine. 2022;85:104294.
   PubMedGoogle Scholar
• Yan L, Liu P, Li X, et al. Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection. Front Microbiol. 2022;12:4273.
   Google Scholar
• Takeuchi JS, Fukunaga A, Yamamoto S, et al. SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Sci Rep. 2022;12(1):15447.
   PubMedGoogle Scholar
• Hurme A, Jalkanen P, Heroum J, et al. Long-Lasting T cell responses in BNT162b2 COVID-19 mRNA vaccinees and COVID-19 convalescent patients. Front Immunol. 2022;13:869990.
   PubMed Web of Science ®Google Scholar
• Jiménez M, Roldán E, Fernández-Naval C, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022;6(3):774–784.
   PubMedGoogle Scholar
• Muchtar E, Koehler AB, Johnson MJ, et al. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022;97(1):90–98.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Screaton correspondence GR. Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13.
   PubMed Web of Science ®Google Scholar
• GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS-CoV-2 omicron–reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7(69).
   Google Scholar
• Moodie Z, Price L, Gouttefangeas C, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010;59(10):1489–1501.
   PubMed Web of Science ®Google Scholar